Add Yahoo as a preferred source to see more of our stories on Google. The therapy was developed through molecular structure screening and functional evaluations. Credit: Sai Thaw Kyar / ...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with ...
Five years ago, scientists watched in wonder as synthetic bacteria grew and split into daughter cells. The bacteria’s extremely stripped-down genome still supported its entire life cycle. It was a ...
BERKELEY, CA, March 10, 2026 (EZ Newswire) -- R3 Bio announced the release of its 2026 research report outlining early-stage progress in developing integrated, stem cell-derived biological platforms ...
The researchers, led by chemistry professor Zan Luthey-Schulten at the University of Illinois Urbana-Champaign, present their findings in the journal Cell. In two videos, researchers describe the work ...
(Nanowerk News) By simulating the life cycle of a minimal bacterial cell — from DNA replication to protein translation to metabolism and cell division — scientists have opened a new frontier of ...
Orca Bio to Present Clinical Data on Its Pipeline of High-Precision Cell Therapies at the 52nd Annual Meeting of the EBMT Patient reported outcomes with Orca-T® from the pivotal Precision-T Phase 3 ...
Orca-T outcomes in patients with myelodysplastic syndromes to be presented for the first time; includes retrospective comparison to PTCy Additional presentations will highlight the combination of Orca ...
‘Tiny biological batteries’ can change the cell membrane’s electrical properties – a discovery that has big implications for health, as many essential cellular processes hinge upon precise electrical ...
The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results